Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Patients with tumor metastasis and known EGFR driving gene mutation;
• •2. Patients who have received any anti-tumor treatment in the past, including radiotherapy, chemotherapy, immunotherapy and anti-tumor treatment with traditional Chinese medicine;
• •3. Imaging (CT or MRI) shows that the tumor invades into the large blood vessels or the border with the blood vessels is unclear; or imaging (CT or MRI) shows that there is any pulmonary cavity or necrotic lesions;
• •4. Patients with any active autoimmune disease or history of autoimmune disease;
• •5. Patients with innate or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or co infection with hepatitis B and hepatitis C;
• •6. Patients with uncontrollable third cavity effusion, such as massive pleural effusion or ascites or pericardial effusion;
• •7. Routine urine test indicated that urine protein was \>= (+ +), or 24-hour urine protein was \>= 1g, or severe liver and kidney dysfunction;
• •8. Subjects requiring systemic treatment with corticosteroids (\> 10 mg / day of prednisone or its equivalent) or other immunosuppressants within 14 days prior to the first administration;
• •9. Patients with other malignant tumors in the past 5 years;
• •10. Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiologic pneumonia, drug-induced pneumonia and active pneumonia confirmed by imaging;
• •11. Patients with uncontrollable hypertension (systolic blood pressure \>= 140 mmHg or diastolic blood pressure \>= 90 mmHg, despite the best drug treatment);
• •12. Patients with cardiac insufficiency;
• •13. Patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including cerebral hemorrhage, cerebral infarction, transient ischemic attack, etc.);
• •14. Patients who underwent major surgery, open biopsy or significant trauma within 28 days before admission;
• •15. Patients with hemoptysis, active bleeding, ulcer, intestinal perforation and intestinal obstruction within 3 months before admission;
• •16. Patients who are taking part in other clinical studies or the time of the first medication is less than 4 weeks from the end of the previous clinical study (the last medication);
• •17. Patients with severe infection or fever of unknown origin \> 38.5 degrees C within 4 weeks before medication;
• •18. Patients with known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• •19. Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures.